In NSCLC cells, acquired resistance to gefitinib or osimertinib has shown EMT characteristics, such as a decrease in E-cadherin and an increase in vimentin and stemness, without any secondary EGFR mutations [275]. The gene discussed is CDH1; the disease is non-small cell lung carcinoma.